{"brief_title": "A Phase I Study of the Safety and Immunogenicity of Rgp 120/HIV-1IIIB Vaccine in HIV-1 Seropositive Adult Volunteers", "brief_summary": "To test the safety and immunogenicity of rgp 120/HIV-1IIIB vaccine in HIV-1 seropositive adult patients.", "condition": ["HIV Infections"], "intervention_type": ["Biological"], "intervention_name": ["rgp120/HIV-1IIIB"], "criteria": "Inclusion Criteria Patients must have the following: - Stage 1 or 2 Walter Reed clinical staging of HIV infected individuals. - The ability to understand and sign a written informed consent form, which must be obtained prior to study entry. - Be available for 24 weeks so that follow up may be completed. - Qualify for care as Department of Defense health care beneficiary. Exclusion Criteria Co-existing Condition: Patients with the following conditions or symptoms are excluded: - Prior history of clinically significant cardiac, pulmonary, hepatic, renal, neurologic or autoimmune disease, other than HIV-1 infection, and in less than average general health as determined by a medical history, physical examination, and the required laboratory test results. Concurrent Medication: Excluded: - Corticosteroids or other known immunosuppressive drugs. - Any experimental agents. Patients with the following are excluded: - Prior history of clinically significant cardiac, pulmonary, hepatic, renal, neurologic or autoimmune disease, other than HIV-1 infection, and in less than average general health as determined by a medical history, physical examination, and the required laboratory test results. Prior Medication: Excluded within 30 days of study entry: - Zidovudine or other anti-retroviral agents.", "gender": "All", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "keyword": "AIDS Vaccines", "mesh_term": ["HIV Infections", "Vaccines"], "id": "NCT00001992"}